Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer

Urology

Volumn 68, Issue 1, 2006, Pages 104-109

  Pinkawa, Michael ^a   Fischedick, Karin ^a   Gagel, Bernd ^a   Piroth, Marc D ^a   Borchers, Holger ^a   Jakse, Gerhard ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CONTROLLED STUDY; DEMOGRAPHY; EDEMA; FOLLOW UP; HEALTH SURVEY; HORMONE ACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RECTUM; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINARY DYSFUNCTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 33745866277     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.01.063     Document Type: Article

References (23)

1. Lim J.D., Hasegawa M., Sikes C., et al. Supra-additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38 (1997) 1071-1078
2. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). a phase III randomised trial. Lancet 360 (2002) 103-108
3. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. a randomized controlled trial. JAMA 292 (2004) 821-827
4. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
5. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
6. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
7. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
8. Feigenberg S.J., Lee W.R., DeSilvio M.L., et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 62 (2005) 956-964
9. Lee R.W., DeSilvio M., Lawton C., et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate. preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys 64 (2006) 804-809
10. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
11. Merrick G.S., Butler W.M., Wallner K.E., et al. Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy. Int J Radiat Oncol Biol Phys 58 (2004) 68-74
12. Potters L., Torre T., Fearn P.A., et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1235-1242
13. Davidson S.E., Burns M.P., Routledge J.A., et al. Assessment of morbidity in carcinoma of the cervix. a comparison of the LENT SOMA scales and the Franco-Italian glossary. Radiother Oncol 69 (2003) 195-200
14. Goldner G., Wachter-Gerstner N., Wachter S., et al. Acute side effects during 3-D-planned conformal radiotherapy of prostate cancer. differences between patient's self-reported questionnaire and the corresponding doctor's report. Strahlenther Onkol 179 (2003) 320-327
15. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
16. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789-799
17. Higano C., Shields A., Wood N., et al. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 64 (2004) 1182-1186
18. Smith M.R. Changes in fat and lean body during androgen-deprivation therapy for prostate cancer. Urology 63 (2004) 742-745
19. Krupski T., Bissonette E.A., Petroni G.R., et al. The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. Eur Urol 43 (2003) 467-472
20. Smith J.C., Bennett S., Evans L.M., et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86 (2001) 4261-4267
21. Osoba D., Rodrigues G., Myles J., et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16 (1998) 139-144
22. Davis J.W., Kuban D.A., Lynch D.F., et al. Quality of life after treatment for localized prostate cancer. differences based on treatment modality. J Urol 166 (2001) 947-952
23. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1048-1055